Propolis is a natural product with many biological properties including hypoglycemic activity and modulating lipid profile. The present study was designed to evaluate the effect of Iranian propolis extract on glucose metabolism, Lipid profile, Insulin resistance, renal and liver function as well as inflammatory biomarkers in patients with type 2 diabetes mellitus (T2DM). A double-blind, placebo-controlled clinical trial was conducted. The duration of the study lasted 90 days. Patients with T2DM were recruited and randomly divided into an Iranian propolis group (1000 mg/day) (n=50) and a placebo group (n=44).There was a significant decrease in the serum levels of glycosylated hemoglobin (HbA1c), 2-hour post prandial (2hpp), insulin, homeostasis model assessment-insulin resistance (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-β), High sensitive C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α). However, the serum HDL-C had significantly increased in the propolis group compared with the placebo group. There was also a significant decrease in serum liver transaminase (ALT and AST) and blood urea nitrogen (BUN) concentrations in the propolis group. Iranian propolis has beneficial effects on reducing post prandial blood glucose, serum insulin, insulin resistanc,e and inflammatory cytokines. It is also a useful treatment for preventing the liver and renal dysfunction, as well as, elevatating HDL-C concentrations in patients with T2DM.
18 - 21 May 2019
European Society of Endocrinology